Cargando…

A recombinant single chain antibody interleukin-2 fusion protein.

Recombinant interleukin-2 (rIL-2) therapy has been shown to be of value in the treatment of some cases of melanoma and renal cell carcinoma. However its use can be limited by severe systemic toxicity. Targeting rIL-2 to the tumour should improve the anti-tumour immune response and decrease the syste...

Descripción completa

Detalles Bibliográficos
Autores principales:	Savage, P., So, A., Spooner, R. A., Epenetos, A. A.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1993
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968162/ https://www.ncbi.nlm.nih.gov/pubmed/8431359

Ejemplares similares

Construction, characterisation and kinetics of a single chain antibody recognising the tumour associated antigen placental alkaline phosphatase.
por: Savage, P., et al.
Publicado: (1993)

Fundamental Characterization of Antibody Fusion-Single-Chain TNF Recombinant Proteins Directed against Costimulatory TNF Receptors Expressed by T-Lymphocytes
por: Nagai, Hodaka, et al.
Publicado: (2023)

A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo
por: Ongaro, Tiziano, et al.
Publicado: (2020)

Characterisation and internalisation of recombinant humanised HMFG-1 antibodies against MUC1
por: Pericleous, L M, et al.
Publicado: (2005)

Generation of a selectively cytotoxic fusion protein against p53 mutated cancers
por: Kousparou, Christina A, et al.
Publicado: (2012)

Functional Analysis of the Thymic Microenvironment Using Recombinant Single Chain Antibodies
por: Palmer, D. B., et al.
Publicado: (2000)

Antibody guided lymphangiography in the staging of cervical cancer.
por: Epenetos, A. A.
Publicado: (1985)

Design, characterization and anti-tumour cytotoxicity of a panel of recombinant, mammalian ribonuclease-based immunotoxins.
por: Deonarain, M. P., et al.
Publicado: (1998)

Monoclonal antibodies for imaging and therapy.
por: Epenetos, A. A., et al.
Publicado: (1989)

Affinity Chromatography of Native and Recombinant Proteins from Receptors for Insulin and IGF-I to Recombinant Single Chain Antibodies
por: Fujita-Yamaguchi, Yoko
Publicado: (2015)

Induction of viral and tumour specific CTL responses using antibody targeted HLA class I peptide complexes
por: Savage, P, et al.
Publicado: (2002)

Development and evaluation of an ELISA using recombinant fusion protein to detect the presence of host antibody to equine arteritis virus
por: Chirnside, E.D., et al.
Publicado: (1995)

Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens.
por: Kosmas, C., et al.
Publicado: (1991)

High-level secretion of recombinant monomeric murine and human single-chain Fv antibodies from Drosophila S2 cells
por: Gilmartin, Allissia A., et al.
Publicado: (2012)

High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells
por: Jäger, Volker, et al.
Publicado: (2013)

Detection of human coronavirus 229E-specific antibodies using recombinant fusion proteins
por: Pohl-Koppe, A., et al.
Publicado: (1995)

PREFERENTIAL RECOMBINATION OF ANTIBODY CHAINS TO FORM EFFECTIVE BINDING SITES
por: Roholt, O. A., et al.
Publicado: (1965)

Design and Characterization of Novel Antibody-Cytokine Fusion Proteins Based on Interleukin-21
por: Di Nitto, Cesare, et al.
Publicado: (2022)

Elevated expression of the interleukin 4 receptor in carcinoma: a target for immunotherapy?
por: Al Jabaari, B., et al.
Publicado: (1989)

Vaccine effect of recombinant single-chain hemagglutinin protein as an antigen
por: Kawai, Atsushi, et al.
Publicado: (2020)

Effect of tumour necrosis factor on the uptake of specific and control monoclonal antibodies in a human tumour xenograft model.
por: Rowlinson-Busza, G., et al.
Publicado: (1995)

RECOMBINATION OF ANTIBODY POLYPEPTIDE CHAINS IN THE PRESENCE OF ANTIGEN
por: Metzger, Henry, et al.
Publicado: (1964)

Conjugation of monoclonal antibodies to a synthetic peptide substrate for protein kinase: a method for labelling antibodies with 32P.
por: Foxwell, B. M., et al.
Publicado: (1988)

Interleukin 2-Based Fusion Proteins for the Treatment of Cancer
por: MacDonald, Alana, et al.
Publicado: (2021)

Fusion of apoptosis‐related protein Cytochrome c with anti‐HER‐2 single‐chain antibody targets the suppression of HER‐2+ breast cancer
por: Lu, DanDan, et al.
Publicado: (2021)

Bifunctional recombinant fusion proteins for rapid detection of antibodies to both HIV-1 and HIV-2 in whole blood
por: Gupta, Amita, et al.
Publicado: (2006)

Fusion Rates of Lateral Lumbar Interbody Fusion Using Recombinant Human Bone Morphogenetic Protein-2
por: Nourian, Ardalan A., et al.
Publicado: (2018)

Xenogeneic monoclonal antibodies in the management of cancer: control of their in vivo immunogenicity and induction of specific unresponsiveness using an antibody-drug immunoconjugate.
por: Sivolapenko, G. B., et al.
Publicado: (1991)

IgG-single-chain TRAIL fusion proteins for tumour therapy
por: Siegemund, Martin, et al.
Publicado: (2018)

Single-Chain Soluble Receptor Fusion Proteins as Versatile Cytokine Inhibitors
por: Holgado, Aurora, et al.
Publicado: (2020)

Production and characterization of a recombinant single-chain antibody against Hantaan virus envelop glycoprotein
por: Yang, Jie, et al.
Publicado: (2009)

Generation of recombinant single-chain antibodies neutralizing the cytolytic activity of vaginolysin, the main virulence factor of Gardnerella vaginalis
por: Pleckaityte, Milda, et al.
Publicado: (2011)

Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins
por: Schneider, B, et al.
Publicado: (2010)

Control of Established Colon Cancer Xenografts Using a Novel Humanized Single Chain Antibody-Streptococcal Superantigen Fusion Protein Targeting the 5T4 Oncofetal Antigen
por: Patterson, Kelcey G., et al.
Publicado: (2014)

IL4‐10 fusion protein: a novel immunoregulatory drug combining activities of interleukin 4 and interleukin 10
por: Steen‐Louws, C., et al.
Publicado: (2018)

Generation and functional characterization of the anti-transferrin receptor single-chain antibody-GAL4 (TfRscFv-GAL4) fusion protein
por: Ye, Qing, et al.
Publicado: (2012)

Enhanced transport of plant‐produced rabies single‐chain antibody‐RVG peptide fusion protein across an in cellulo blood–brain barrier device
por: Phoolcharoen, Waranyoo, et al.
Publicado: (2017)

Development of a novel bi-specific monoclonal antibody approach for tumour targeting
por: Koumarianou, A A, et al.
Publicado: (1999)

An anti-MUC1-antibody–interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells
por: Heuser, C, et al.
Publicado: (2003)

Generation and utility of a single-chain fragment variable monoclonal antibody platform against a baculovirus expressed recombinant receptor binding domain of SARS-CoV-2 spike protein
por: Salem, Reda, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hh4eo5ffqj3s7n08u5gat2a7ub